This 12-month open-label, but dose-blinded extension phase,
evaluated the safety and tolerability of flexibly-dosed edivoxetine (6, 9, 12 or 18 mg once
daily) in patients (N = 397)
with major depressive disorder, who completed the 10-week randomized,
double-blind, placebo-controlled acute phase of the study.All patients were
treated with edivoxetine during the extension phase. The mean age of the patients was 45
years, and most were white females.
Safety evaluations included assessment of treatment-emergent adverse events
(TEAEs), laboratory and vital sign measures, and suicidality. Within-group
t-tests based on a 2-sided significance level of 0.05 and 95% confidence levels
were used to assess whether changes from baseline were statistically
significant from zero. The overall completion rate was 54%. Adverse event was
the most common (14.4%) reason for discontinuation, which included blood
pressure increased (1.3%), heart rate increased (1.3%), anxiety (1.0%), and
tachycardia (1.0%). At least 1 TEAE was reported by 72.3% of patients, of which
headache (10.8%) and hyperhidrosis (10.1%) were the most common; 2.8% of
patients had ≥1 serious adverse events, and there were no completed suicides. No clinically relevant changes were
observed in most laboratory measures. Potentially clinically significant
changes in ALT values occurred in 1.8% of patients, and either normalized or
had decreased by the last
assessment. Mean increases in blood pressure and pulse were consistent with
those observed in the acute phase and appeared to reach a plateau within 3 to 5
months of treatment. In conclusion, safety and tolerability findings during
this long-term extension phase evaluation of edivoxetine were consistent with
its norepinephrine reuptake inhibition profile.
Cite this paper
Oakes, T. , Martinez, J. , Dellva, M. , Goldberger, C. , Pangallo, B. , Bangs, M. , Ahl, J. and White, W. (2014) Safety and Tolerability of Edivoxetine for Long-Term Treatment of Major Depressive Disorder in Adult Patients. Open Journal of Psychiatry
, 131-140. doi: 10.4236/ojpsych.2014.42017
 Hirschfeld, R.M. (2001) Clinical Importance of Long-Term Antidepressant Treatment. British Journal of Psychiatry, 42, S4-S8. http://dx.doi.org/10.1192/bjp.179.42.s4
 Greden, J.F. (2001) The Burden of Recurrent Depression: Causes, Consequences, and Future Prospects. Journal of Clinical Psychiatry, 62(Suppl 22), 5-9.
 Keller, M.B. (2002) Rationale and Options for the Long-Term Treatment of Depression. Human Psychopharmacology, 17, S43-S46. http://dx.doi.org/10.1002/hup.400
 Stahl, S.M., Zhang, L., Damatarca, C. and Grady, M. (2003) Brain Circuits Determine Destiny in Depression: A Novel Approach to the Psychopharmacology of Wakefulness, Fatigue, and Executive Dysfunction in Major Depressive Disorder. Journal of Clinical Psychiatry, 64(Suppl 14), 6-17.
 Pangallo, B., Dellva, M.A., D’Souza, D.N., Essink, B., Russell, J. and Goldberger, C. (2011) A Randomized, Double-Blind Study Comparing LY2216684 and Placebo in the Treatment of Major Depressive Disorder. Journal of Psychiatric Research, 45, 748-755. http://dx.doi.org/10.1016/j.jpsychires.2011.03.014
 Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R. and Dunbar, G.C. (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): The Development and Validation of a Structured Diagnostic Psychiatric Interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59(Suppl 20), 22-33.
 Williams, J.B., Kobak, K.A., Bech, P., Engelhardt, H., Evans, K., Lipsitz, J., Olin, J., Pearson, J. and Kalali, A. (2008) The GRID-HAMD: Standardization of the Hamilton Depression Rating Scale. International Clinical Psychopharmacology, 23, 120-129. http://dx.doi.org/10.1097/YIC.0b013e328 2f948f5
 Guy, W. (1976) Clinical Global Impressions, ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ. No. ADM 76-338). National Institute of Mental Health, Rockville, 218-222.
 Posner, K., Brown, G.K., Stanley, B., Brent, D.A., Yershova, K.V., Oquendo, M.A., Currier, G.W., Melvin, G.A., Greenhill, L., Shen, S. and Mann, J.J. (2011) The Columbia-Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings from Three Multisite Studies with Adolescents and Adults. American Journal of Psychiatry, 168, 1266-1277. http://dx.doi.org/10.1176/appi.ajp.2011.10111704
 Montgomery, S.A. and ?sberg, M. (1979) A New Depression Scale Designed to be Sensitive to Change. British Journal of Psychiatry, 134, 382-389.